RxDoctor Payments Data

Harish Bhaskar, MD

Pulmonary Disease · Jacksonville, FLNPI 1750506705

Payments from drug & device makers

$186,372in general payments, 2019–2025

Across 154 payments — averaging $1210.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$177K
  • Intuitive Surgical$5K
  • Pulmonx Corporation$2K
  • Inari Medical, Inc.$748
  • Actelion Pharmaceuticals US, Inc.$411
  • Genentech USA, Inc.$284
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$3,08231%
  • Food & beverage$3,57336%
  • Education$3,10631%
  • Gifts$1371%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$186,372 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$105,771
Medicare patients
511
Services billed
1,184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan189$2,378,719
AdempasRiociguat121$1,653,936
UptraviSelexipag63$1,404,884
Orenitram ErTreprostinil Diolamine31$585,290
Trelegy ElliptaFluticasone/Umeclidin/Vilanter273$266,976
Tyvaso DpiTreprostinil11$257,683
OfevNintedanib Esylate21$255,491
Ambrisentan27$117,363
Breztri AerosphereBudesonide/Glycopyr/Formoterol132$89,858
Dupixent PenDupilumab22$82,508
Breo ElliptaFluticasone/Vilanterol84$46,639
Tadalafil31$37,729
Stiolto RespimatTiotropium Br/Olodaterol Hcl52$29,473
Spiriva RespimatTiotropium Bromide36$24,378
XolairOmalizumab11$24,151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Bosentan$411$3,804,769269 claims
BayerAdempas$11$1,653,936121 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$67$336,983402 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$196$309,342109 claims
AstraZenecaBreztri Aerosphere, Symbicort$42$107,077178 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →